Research of Tolvaptan prescription in SIADH patients (Observational research using DPC)
Not Applicable
- Conditions
- SIADH
- Registration Number
- JPRN-UMIN000046985
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd. Medical Affairs Department
- Brief Summary
As a result of examination using actual clinical data using the DPC database, half of the tolvaptan starting dose to SIADH was started from a low dose (3.75 mg), and the average administration period was 32.7 days for 3.75 mg and 33.1 days for 7.5 mg. Since mean of the serum sodium concentration at the start of the tolvaptan-administered case was 120.30 mEq / L, it is considered that the appropriate starting dose was selected for administration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2800
Inclusion Criteria
Not provided
Exclusion Criteria
- Patients under 18 years old
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -Tolvaptan prescription in actual clinical practice (starting dose, increase / decrease, prescription period, re-administration) - Changes in serum sodium concentration, occurrence of rapid correction of hyponatremia (by Tolvaptan dose)
- Secondary Outcome Measures
Name Time Method -Patient demographic and clinical characteristics